AnalystsInsight

Joon Lee (UBS): Analyst Track Record and Price‑Target Accuracy

How often Joon Lee’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,082 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Joon Lee ranks #114 of 1,000 analysts in Exent’s scoring (5.0★).
  • 33.6% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 136 days; 60.0% of calls were up 12 months later.
  • Most‑covered stocks: PRAX, WVE, CORT, JAZZ.

Joon Lee’s track record at a glance

Joon Lee of UBS ranks #114 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 33.6% of Joon’s price targets were reached, 18.8 points below the 52.4% average across all analysts.

MetricJoon LeeAll analysts
Price‑target hit rate33.6%52.4%
Median days to hit target136 days91 days
Calls up after 12 months60.0%64.0%
Median 12‑month return of calls+13.4%+13.4%
Hit rate, last 2 years34.6%—
Average worst drop after a call−29.0%—
Ratings in the sample1,082—
Stocks covered29—

How fast price targets were reached

Time to reach the targetJoon Lee
Under 30 days19.2%
30–90 days17.0%
90–180 days25.5%
Over 180 days38.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Joon Lee covers most

StockRatings in the sample
PRAX37
WVE36
CORT34
JAZZ31
PTCT31
ANAB21
TSHA21
VKTX19

In the past year Joon’s ratings were 93% Buy, 7% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Jun 9, 2026JAZZInitiated CoverageBuy$256.00
Mar 17, 2026VYGRReiterated: BuyBuy$0.00
Mar 17, 2026EDITReiterated: HoldHold$0.00
Mar 17, 2026VYGRMaintainedBuy—
Mar 17, 2026EDITMaintainedHold—
Mar 17, 2026VYGRMaintained: BuyBuy$0.00
Mar 17, 2026EDITMaintained: HoldHold$0.00
Mar 13, 2026SLDBReiterated: BuyBuy$0.00
Mar 13, 2026SLDBMaintained: BuyBuy$0.00
Mar 13, 2026SLDBMaintainedBuy—
Mar 12, 2026PRAXReiterated: BuyBuy$700.00
Mar 12, 2026PRAXReiteratedBuy$700.00
  • Jun 9, 2026
    Stock
    JAZZ
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $256.00
  • Mar 17, 2026
    Stock
    VYGR
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Mar 17, 2026
    Stock
    EDIT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Mar 17, 2026
    Stock
    VYGR
    Action
    Maintained
    Rating
    Buy
    Price target
    —
  • Mar 17, 2026
    Stock
    EDIT
    Action
    Maintained
    Rating
    Hold
    Price target
    —
  • Mar 17, 2026
    Stock
    VYGR
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $0.00
  • Mar 17, 2026
    Stock
    EDIT
    Action
    Maintained: Hold
    Rating
    Hold
    Price target
    $0.00
  • Mar 13, 2026
    Stock
    SLDB
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Mar 13, 2026
    Stock
    SLDB
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $0.00
  • Mar 13, 2026
    Stock
    SLDB
    Action
    Maintained
    Rating
    Buy
    Price target
    —
  • Mar 12, 2026
    Stock
    PRAX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $700.00
  • Mar 12, 2026
    Stock
    PRAX
    Action
    Reiterated
    Rating
    Buy
    Price target
    $700.00

Live ratings from Joon Lee and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 19, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows Joon Lee’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Joon Lee ranks #114 of 1,000 with a 5.0★ rating. 33.6% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 60.0% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Joon Lee’s success rate is 54.8% by the ranking source and 33.6% by Exent’s price-target hit-rate backtest, with a median of 136 days to reach a target.

Joon Lee (UBS) covers 29 stocks, mostly in healthcare. The most frequently rated are PRAX, WVE, CORT, JAZZ, PTCT.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.